SG11201703579UA - Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines - Google Patents

Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines

Info

Publication number
SG11201703579UA
SG11201703579UA SG11201703579UA SG11201703579UA SG11201703579UA SG 11201703579U A SG11201703579U A SG 11201703579UA SG 11201703579U A SG11201703579U A SG 11201703579UA SG 11201703579U A SG11201703579U A SG 11201703579UA SG 11201703579U A SG11201703579U A SG 11201703579UA
Authority
SG
Singapore
Prior art keywords
difluoromethyl
aminopyrimidines
aminopyridines
Prior art date
Application number
SG11201703579UA
Other languages
English (en)
Inventor
Vladimir Cmiljanovic
Paul Hebeisen
Florent Beaufils
Thomas Bohnacker
Denise Rageot
Alexander Sele
Matthias Wymann
Jean-Baptiste Langlois
Original Assignee
Piqur Therapeutics Ag
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piqur Therapeutics Ag, Univ Basel filed Critical Piqur Therapeutics Ag
Publication of SG11201703579UA publication Critical patent/SG11201703579UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
SG11201703579UA 2014-11-11 2015-11-10 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines SG11201703579UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192617 2014-11-11
PCT/EP2015/076192 WO2016075130A1 (en) 2014-11-11 2015-11-10 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines

Publications (1)

Publication Number Publication Date
SG11201703579UA true SG11201703579UA (en) 2017-05-30

Family

ID=51868133

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703579UA SG11201703579UA (en) 2014-11-11 2015-11-10 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines

Country Status (23)

Country Link
US (3) US10640516B2 (ru)
EP (1) EP3218358B1 (ru)
JP (1) JP6689843B2 (ru)
KR (1) KR20170101899A (ru)
CN (1) CN107108644B (ru)
AU (1) AU2015345233B2 (ru)
CA (1) CA2965565C (ru)
CY (1) CY1124444T1 (ru)
DK (1) DK3218358T3 (ru)
ES (1) ES2886008T3 (ru)
HR (1) HRP20211336T1 (ru)
HU (1) HUE055473T2 (ru)
IL (1) IL252216B (ru)
MA (1) MA40933A (ru)
MX (1) MX2017006152A (ru)
PH (1) PH12017500854A1 (ru)
PL (1) PL3218358T3 (ru)
PT (1) PT3218358T (ru)
RS (1) RS62289B1 (ru)
RU (1) RU2712091C2 (ru)
SG (1) SG11201703579UA (ru)
SI (1) SI3218358T1 (ru)
WO (1) WO2016075130A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
PL3371190T3 (pl) 2015-11-06 2022-11-07 Incyte Corporation Związki heterocykliczne jako inhibitory pi3k-gamma
EP3400221B1 (en) 2016-01-05 2020-08-26 Incyte Corporation Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
JP7118509B2 (ja) 2016-05-18 2022-08-16 トルク アーゲー 皮膚病変の治療
JP6991158B2 (ja) 2016-05-18 2022-02-10 ピクール セラピューティクス アーゲー 神経障害の治療法
EP3458035A1 (en) * 2016-05-18 2019-03-27 PIQUR Therapeutics AG Treatment of skin lesions
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
CN107266422A (zh) * 2017-06-12 2017-10-20 西安交通大学 2‑(5‑嘧啶基)‑4‑吗啉基‑6‑取代均三嗪类化合物及其盐、制备方法和应用
TWI803525B (zh) 2017-10-18 2023-06-01 美商英塞特公司 作為PI3K-γ 抑制劑之三級醇
CN109810100B (zh) * 2017-11-21 2022-03-11 中国药科大学 含有苯并呋喃的parp-1和pi3k双靶点抑制剂
IL274132B2 (en) * 2017-11-23 2024-02-01 Piqur Therapeutics Ag Treatment of skin problems
EP3833784A1 (en) 2018-08-07 2021-06-16 PIQUR Therapeutics AG Treatment of squamous cell carcinoma
KR20210091121A (ko) 2018-09-05 2021-07-21 인사이트 코포레이션 포스포이노시티드 3-키나아제 (pi3k) 억제제의 결정질 형태
CN113906026A (zh) * 2019-06-06 2022-01-07 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN111039874B (zh) * 2019-12-13 2022-11-04 南开大学 一种2-胺基-4-甲基嘧啶化合物的零废水制备方法
KR20210158019A (ko) 2020-06-23 2021-12-30 주식회사 온코빅스 포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2022214701A1 (en) * 2021-04-09 2022-10-13 Universität Basel Triazine derivative as covalent inhibitors of pi3k
CN116239580A (zh) * 2023-03-06 2023-06-09 中国药科大学 三嗪类化合物及其制备方法、药物组合物和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071189B2 (en) * 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
KR101296884B1 (ko) 2005-03-11 2013-08-14 젠야쿠코교가부시키가이샤 활성 성분으로서 헤테로시클릭 화합물을 포함하는 면역억제제 및 항암제
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20090108124A (ko) 2007-02-06 2009-10-14 노파르티스 아게 Pi 3-키나제 억제제 및 그의 사용 방법
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CN104245693B (zh) * 2012-12-14 2016-08-24 上海恒瑞医药有限公司 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR20170101899A (ko) 2017-09-06
RU2712091C2 (ru) 2020-01-24
US10640516B2 (en) 2020-05-05
EP3218358A1 (en) 2017-09-20
RU2017111265A (ru) 2018-12-14
HRP20211336T1 (hr) 2021-11-26
PH12017500854A1 (en) 2017-11-06
AU2015345233A1 (en) 2017-05-25
US20200277304A1 (en) 2020-09-03
DK3218358T3 (da) 2021-08-30
PL3218358T3 (pl) 2022-03-14
PT3218358T (pt) 2021-09-10
JP2017533246A (ja) 2017-11-09
AU2015345233B2 (en) 2020-01-02
JP6689843B2 (ja) 2020-04-28
CA2965565A1 (en) 2016-05-19
US11186591B2 (en) 2021-11-30
NZ731504A (en) 2021-04-30
MA40933A (fr) 2017-09-19
IL252216B (en) 2021-12-01
BR112017009457A2 (pt) 2017-12-19
SI3218358T1 (sl) 2021-10-29
CN107108644B (zh) 2021-01-05
RU2017111265A3 (ru) 2019-02-19
WO2016075130A1 (en) 2016-05-19
US20220153752A1 (en) 2022-05-19
EP3218358B1 (en) 2021-06-16
CN107108644A (zh) 2017-08-29
ES2886008T3 (es) 2021-12-16
US20190031682A1 (en) 2019-01-31
IL252216A0 (en) 2017-07-31
RS62289B1 (sr) 2021-09-30
MX2017006152A (es) 2017-07-19
CA2965565C (en) 2023-09-19
CY1124444T1 (el) 2022-07-22
HUE055473T2 (hu) 2021-11-29
BR112017009457A8 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
PL3215147T3 (pl) Związki norketaminy osłabiającej działanie układu nerwowego i sposoby
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
GB201401617D0 (en) Novel combination and use
HK1243950A1 (zh) 新型組合物和用途
SG11201704473WA (en) New methods and uses
HK1243342A1 (zh) 化合物和方法
HK1243077A1 (zh) 呱啶基吡唑並嘧啶酮及其用途
GB201416727D0 (en) Use
IL254241A0 (en) Etv2 and its uses
GB201416716D0 (en) Use
HK1220676A1 (zh) 配置件和方法
GB201419650D0 (en) Modified heterocyclase
GB201408091D0 (en) Methods and uses
GB201416082D0 (en) Method and uses
GB2545167B (en) Cloches and use thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201416073D0 (en) Methods and uses
GB201416086D0 (en) Methods and uses
PT2923578T (pt) Método para a produção de um produto alimentar
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning
GB201404301D0 (en) Compounds and combinations
GB201420534D0 (en) Use
GB201420365D0 (en) Use